
    
      A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28
      Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10
      mg in T2DM Patients aged 10-24 years
    
  